us
regulator
rule
pain
drug
us
food
drug
regulators
decide
friday
whether
recommend
sale
painkillers
linked
high
risk
heart
attack
stroke
food
drug
administration
fda
advisory
panel
give
verdict
hearing
evidence
three
days
painkillers
called
cox
inhibitors
sold
brand
names
celebrex
vioxx
vioxx
withdrawn
shops
last
year
merck
said
would
consider
selling
gets
fda
approval
fda
asked
decide
benefits
patients
justify
increased
risks
putting
vioxx
back
shelves
likely
boost
profits
merck
make
easier
legal
battles
people
claim
injured
drug
analysts
said
merck
voluntarily
stopped
sales
vioxx
september
move
caused
firms
fourthquarter
earnings
slide
bn
â£m
bn
year
earlier
mercks
shares
tumbled
news
company
set
aside
millions
dollars
cover
cost
vioxxrelated
litigation
alarm
bells
rung
research
note
called
approve
showed
risk
heart
attack
stroke
doubled
patients
taking
drug
least
months
cox
inhibitors
developed
drug
companies
including
merck
pfizer
cause
users
fewer
stomach
problems
painkillers
pfizer
still
selling
celebrex
bextra
products
though
investigations
suggested
may
also
harmful
heart
mercks
announcement
possible
reintroduction
vioxx
caught
analysts
surprise
mercks
head
research
peter
kim
said
withdrew
vioxx
based
information
available
us
time
knowing
alternative
therapies
went
say
things
since
changed
light
new
reports
given
new
information
clear
cardiovascular
risk
observed
approve
makes
vioxx
unique
class
similar
drugs
marketed
us
mr
kim
explained
thursday
david
graham
fdas
office
drug
safety
told
advisory
panel
really
doesnt
appear
need
cox
inhibitors
according
calculations
presented
us
senate
dr
graham
november
vioxx
may
linked
many
american
deaths
facing
stem
criticism
handling
vioxx
case
fda
said
tuesday
create
independent
body
oversee
safety
drugs
already
market
place
european
regulators
meanwhile
ruled
thursday
patients
heart
disease
stroke
take
cox
inhibitors
european
medicines
agency
also
said
doctors
cautious
giving
drugs
patients
risk
factors
heart
disease
